Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, provides insights into how society needs to be made ready for Alzheimer’s disease modifying therapies. He highlights that improved early diagnosis methods could lead to an influx of patients, and the importance of doctors following treatment guidelines. Prof. Winblad acknowledges that GPs and memory clinics will both be under pressure. As well optimizing access to diagnosis, payment models will need to be established given the costs associated with treatment and the high number of MRIs needed to assess patients on the new anti-amyloid therapies. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
